• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Giora Sharf Discusses Ways to Represent the CML Patient Voice

Video

There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.

Becoming active participants in their own care by understanding treatments and becoming a full partner with their physicians is not the extent to which patients with chronic myelogenous leukemia (CML) can make sure their voices are heard, Giora Sharf, co-founder of the CML Advocates Network, said at the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, California.

In addition to empowering patients by educating them with materials like patient-friendly guidelines to CML treatment, his network is partnered with companies and researchers so the patient voice can be heard during the research and development process and they can be represented throughout the entire process.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
Frederick L. Locke, MD, Moffitt Cancer Center and Research Institute
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Andrew Kuykendall, MD, Moffitt Cancer Center
Screenshot of an interview with Shaun McKenzie, MD
Sabarish Ayyappan, MD
Sabarish Ayyappan, MD
Frederick L. Locke, MD
Screenshot of an interview with Shaun McKenzie, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.